A patent covering Bio-Technology General Corp.'s geneticallyengineered thrombus imaging agent Imagex will issue to theIselin, N.J., company next week. The claims of the patent, U.S.No. 5,270,030, are directed to an imaging agent, a plasmidexpressing the agent and the purified polypeptide itself.
Bio-Technology General's (NASDAQ:BTGC) product Imagex is thegenetically engineered domain of the fibronectin molecule thatbinds to fibrin found in blood clots. The agent will be linked toa radioactive entity for detection purposes.
(c) 1997 American Health Consultants. All rights reserved.